Table 3

Comparison of α6 integrin and uPAR expression and clinicopathological findings

Strong co-expression both of α6 integrin and uPAR

ap value


Yes (n = 16)

No (n = 26)

0.011


Gender

Male/Female

11/5

16/10

N.S.

Age (year)

64.4 ± 8.6

64.3 ± 9.5

N.S.

TNM stage

I/II/III/IV

2/1/6/7

7/4/12/3

N.S.

Location

H/B, T

12/4

20/6

N.S.

Liver metastasis

Yes/No

7/9

3/23

0.019

Lymph node matastasis

Yes/No

13/3

13/13

0.045

Cancer cell differentiation

P/Muc/W/Mod

1/0/4/11

2/3/13/8

N.S.

Retroperitoneal invasion

Yes/No

14/2

15/11

0.045

Intrapancreatic nerve invasion

Yes/No

14/2

17/9

N.S.

Lymphatic system invasion

Yes/No

15/1

20/6

N.S.

Venous system invasion

Yes/No

15/1

20/6

N.S.


uPAR, urokinase plasminogen activator receptor; H, head of pancreas; B, body of pancreas; T, tail of pancreas; P, papillary adenocarcinoma; Muc, mucinous carcinoma; W, well-differentiated adenocarcinoma; Mod, moderatery-differentiated adenocarcinoma. The pT, pN, and pM categories were determined according to the TNM classification [19]. The ap-values were obtained using the Mann-Whiteny U test. Values of age are given mean ± s.d. N.S., no significant.

Sawai et al. BMC Cell Biology 2006 7:8   doi:10.1186/1471-2121-7-8

Open Data